×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Non-Hodgkin Lymphoma

Beth Fand Incollingo
Treating relapsed Waldenstrom’s macroglobulinemia takes an individualized approach from a growing list of options.
Jessica Skarzynski
Here are the top 5 CURE stories for July 2019.
Valerie David
Three-time cancer survivor and one-woman show writer and performer, Valerie David, sat down with CURE® to discuss life as a survivor.
Jerry Bridges, M.S.N., RN, CNP
This essay describes my journey with non-Hodgkin lymphoma — peripheral T-cell, not otherwise specified — and my most extraordinary nurse, Xuan Arnette, RN, OCN.
Alexandra Guadagno
From landmark Senate legislation to the Pink Lemonade Stand Challenge, here’s what is making headlines in the cancer space this week.
Kristie L. Kahl
With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.
Jessica Skarzynski
The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.
Following a discussion on the multidisciplinary management of Waldenström Macroglobulinemia, Steven P. Treon, MD, PhD, reflects on the future management of this disease.
 
Steven P. Treon, MD, PhD, provides insight on balancing safety and efficacy while treating Waldenström macroglobulinemia with BTK inhibitors.
Key opinion leader Steven P. Treon, MD, PhD, reviews the advent of targeted therapy for patients with Waldenström macroglobulinemia.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×